Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A Harper
Safety, Tolerability and Sustained Weight Loss Over 2 Years With the Once-Daily Human GLP-1 Analog, Liraglutide
International Journal of Obesity
Nutrition
Endocrinology
Dietetics
Medicine
Metabolism
Diabetes
Sovetovat' Li Patsientam S Ozhireniem Priderzhivat'sya Diety Atkinsa?
Obesity and Metabolism
Internal Medicine
Nutrition
Endocrinology
Public Health
Environmental
Dietetics
Occupational Health
Metabolism
Diabetes
Related publications
DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes
Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211): A 12-Week, Double-Blind, Randomized, Controlled Trial
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes
Adherence to GLP-1 Receptor Agonist Therapy Administered by Once-Daily or Once-Weekly Injection in Patients With Type 2 Diabetes in Germany
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal Medicine
Pharmacology
Adherence to Liraglutide Once Daily or Exenatide Once Weekly Over a 12-Month Period Among Commercially Insured Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
GLP-1 Analog Liraglutide-Induced Cardiac Dysfunction Due to Energetic Starvation in Heart Failure With Non-Diabetic Dilated Cardiomyopathy
Cardiovascular Diabetology
Internal Medicine
Cardiology
Endocrinology
Cardiovascular Medicine
Metabolism
Diabetes
Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation Through a Calcium and AMPK Dependent Mechanism
PLoS ONE
Multidisciplinary
Dulaglutide: Third Once-Weekly GLP-1 Agonist for Type 2 Diabetes
Pharmacy Today
Combining SGLT2 Inhibitor and GLP-1 Agonist: Exaggerated Weight Loss in a Morbidly Obese Patient With Type 2 Diabetes
British Journal of Diabetes
Safety and Tolerability of the Novel Inhaled Corticosteroid Fluticasone Furoate in Combination With the Β2agonist Vilanterol Administered Once Daily for 52 Weeks in Patients ≥12 Years Old With Asthma: A Randomised Trial
Thorax
Pulmonary
Respiratory Medicine